Aspirin use in the prevention of cardiovascular events has been a mainstay of treatment
for decades. However, the use of aspirin in primary prevention of atherosclerotic
cardiovascular disease has recently come under scrutiny. Several recent studies have
evaluated the use of aspirin in primary prevention and the results suggest that in
many patients the risks may outweigh the benefits. Closer examination of these trials
suggests that the use of aspirin therapy for primary prevention may have a role but
likely needs a more tailored approach and that caution is needed in prescribing aspirin
for primary prevention. In conclusion, in this article we review the evolving evidence
for aspirin in the primary prevention of atherosclerotic cardiovascular disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- One hundred years of aspirin.Lancet. 1997; 350: 437-439
- Coronary thrombosis can be prevented.J Insur Med. 1950; 5: 47-48
- Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.Br J Clin Pharmacol. 2011; 72: 619-633
- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.Lancet. 1988; 2: 349-360
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002; 324: 71-86
- 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation. 2014; 129: S49-S73
- Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology.J Am Coll Cardiol. 2018; 73: 3153-3167
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2019; 73: 3168-3209
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Hypertension. 2018; 71: 1269-1324
- Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials.Eur Heart J. 2019; 40: 607-617
- Final report on the aspirin component of the ongoing Physicians' Health Study.N Engl J Med. 1989; 321: 129-135
- Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.JAMA. 2008; 300: 2134-2141
- The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.BMJ. 2008; 337: a1840
- Use of Aspirin to Reduce Risk of Initial Vascular Events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.Lancet. 2018; 392: 1036-1046
- Effects of aspirin for primary prevention in persons with diabetes mellitus.N Engl J Med. 2018; 379: 1529-1539
- Effect of aspirin on disability-free survival in the healthy elderly.N Engl J Med. 2018; 379: 1499-1508
- Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.JAMA. 2019; 321: 277-287
- Aspirin for primary prevention: clinical considerations in 2019.JAMA. 2019; 321: 253-255
- ASCVD Risk Estimator Plus.2014
- Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.Circ Cardiovasc Qual Outcomes. 2014; 7: 453-460
- 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).Eur Heart J. 2016; 37: 2315-2381
- Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines.J Am Coll Cardiol. 2015; 65: 1361-1368
- Should aspirin be used for primary prevention in the post-statin era?.N Engl J Med. 2018; 379: 1572-1574
- Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment.JAMA Intern Med. 2016; 176: 1195-1204
Article info
Publication history
Published online: September 09, 2019
Received in revised form:
August 13,
2019
Received:
June 22,
2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
